Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus VIRILON.
TESTOSTERONE ENANTHATE vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
50-400 mg intramuscularly every 2-4 weeks
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category D/X
Category C
Androgen
Androgen